17.03.2017 - 13:15

Novo Nordisk Foundation Awards for professors at two Nordic EMBL partnership nodes

Two leading scientists from two Nordic EMBL Partnership sites, DANDRITE and MIMS, have been awarded prestigious prizes from the Novo Nordisk foundation.

Poul Nissen, Professor at Aarhus University, and the Director of the the Danish Research Institute of Translational Neuroscience (DANDRITE), the Danish partner of the Nordic EMBL Partnership for Molecular Medicine, has been awarded the Novo Nordisk Prize for his pioneering studies into the structure and function of ion pumps. The Novo Nordisk Prize recognizes unique medical research, or other research contributions, that benefit medical science. The Prize is accompanied by DKK 3 million, awarded by the Novo Nordisk Foundation

Professor Emmanuelle Charpentier, Director of the Department of Regulation in Infection Biology at the Max Planck Institute for Infection Biology in Berlin, Germany and Visiting Professor and Group Leader at The Laboratory for Molecular Infection Medicine Sweden (MIMS), the Swedish partner of the Nordic EMBL Partnership for Molecular Medicine at Umeå University, has been awarded the 2017 Novozymes Prize for her pioneering research on the CRISPR-Cas9 technology. She receives the prize together with Professor Virginijus Siksnys of Vilnius University in Lithuania. The Novozymes Prize recognizes pioneering research, or a technological contribution, that benefits the development and advancement of biotechnology science. This is the first time that two researchers have shared the Prize, which is accompanied by DKK 3 million. 

The two Prizes will be presented in a special ceremony today,  Friday 17 March.

 

FIMM is very proud to join in the congratulations of these two outstanding recipients of the Novo Nordisk prizes. Both have done ground-breaking basic research and illustrate the value of world class research institutes for Nordic and European science and society.

- Jaakko Kaprio, Director of FIMM

Research collaborations and the Nordic EMBL

These Novo Nordisk Foundation awards are awarded to two representatives from the Nordic EMBL Partnership nodes, who have been able to draw on the support, expertise and resources of a wide and collaborative research network. The awards are also a warm recognition by the Novo Nordisk Foundation of the Nordic EMBL Partnership and its importance for helping facilitate original, ground-breaking research across the Nordic region. 

 

Poul Nissen's research

Professor Nissen’s research has primarily harnessed protein crystallography to determine the three-dimensional structure of ion pumps down to the atomic level thereby also explaining the effects of e.g. disease mutations and regulatory interactions. His research has also led to the setting up of companies and industry collaborations.

Read more about the award and Professor Nissen’s research on the following websites:

Novo Nordisk Foundation (link to news article)

DANDRITE (link to news article)

 

Emmanuelle Charpentier's research

Professor Charpentier performed research that led to the development of the CRISPR-Cas9 technology, during her time as a group leader at the MIMS and Umeå University. This ground-breaking gene-editing tool has enabled researchers to precisely and efficiently edit genes in various organisms and cell types, including bacteria, plants and human cells. 

Read more about the award and Emmanuelle Charpentier’s research on the following websites:

Novo Nordisk Foundation (link to news article)

Max Planck Institute (link to news article)

MIMS (link to news article)

 

 

Last updated: 17.03.2017 - 16:37